Clinical trials
Pregnancy, High Risk clinical trials
Below are recruiting pregnancy, high risk clinical trials, each written for real people, not researchers. We’re tracking 362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT03896269RecruitingPhase 1
CPX-351 for high-risk MDS or CMML that came back
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Houston, TexasAges 18 years+ - NCT03775954Recruiting
Fetal heart testing in high-risk pregnancies after baby loss
This study checks unborn babies’ heart signals using special scans during pregnancy and then checks the baby’s heart shortly after birth. It may help researchers understand why certain high-risk pregnancies can lead to fetal demise and improve care.
Madison, WisconsinAges 18 years+ - NCT03152058RecruitingPhase 2
Certolizumab for pregnancy in people with APS
This Phase 2 study tests whether certolizumab can improve pregnancy outcomes in people with antiphospholipid syndrome (APS). It targets pregnancy complications related to APS while closely checking safety, infections, and certain health conditions.
New York, New YorkAges 18–40 - NCT05345860Recruiting
Using MRD results to guide extra treatment after breast surgery
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07688252RecruitingPhase 1
Immunotherapy and chemotherapy for newly diagnosed high-risk neuroblastoma
This trial tests a new drug combination (dinutuximab-beta plus chemotherapy) for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if adding this targeted therapy to standard chemo improves outcomes.
Taipei, TaiwanAges 1–30 - NCT07420465Recruiting
Heart and metabolic risks in pregnancy and after birth
This study looks at heart and metabolic health during late pregnancy and after delivery, tracking both healthy women and those with complications like high blood pressure or diabetes in pregnancy. The goal is to understand how these risks change and what can be done to improve long-term health.
AccraAges 18–45 - NCT07380217Recruiting
Using heart pump support for complex high-risk procedures
This trial is testing whether using a special heart pump (PulseCath iVAC2L) during complex, high-risk angioplasty can help people with very weak hearts. It's for people who need a procedure for complicated coronary artery blockages.
AmsterdamAges 18 years+ - NCT06430853Enrolling by invitation
Pregnancy support study for moms with anxiety or depression
This study tests if a mental health program during pregnancy can help mothers with past or current anxiety or depression. You'll get support and you may feel better and have a healthier pregnancy.
Stanford, CaliforniaAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT07710534RecruitingPhase 2
A study of decitabine-cedazuridine and venetoclax for blood cancers
This trial tests a combination of two drugs (decitabine-cedazuridine and venetoclax) that are given in a low-dose, frequent schedule (metronomic) for people with certain blood cancers that have come back or not responded to treatment. The goal is to see if this combo can help control the disease.
Richmond, VirginiaAges 18 years+ - NCT07301866RecruitingPhase 1/Phase 2
Testing an improved dose of UM171 for cord blood transplant
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Montreal, QuebecAges 18–67 - NCT05317585Recruiting
Continuous glucose monitor use during early pregnancy with type 2 diabetes
This study tests whether using a continuous glucose monitor during pregnancy is useful for people with type 2 diabetes. It may help track blood sugar levels more closely to support safer pregnancy care.
Worcester, MassachusettsAges 18 years+ - NCT07786714Recruiting
Faster brain stimulation for early psychosis risk
This study tests a faster type of brain stimulation, called accelerated neuromodulation therapy, in people who have early signs that could lead to psychosis. The goal is to see if this treatment can help reduce symptoms and improve daily life.
Verdun, QuebecAges 18–34 - NCT06574126RecruitingPhase 2
CAR T-cell therapy for high-risk smoldering myeloma
This trial tests a new CAR T-cell therapy (cilta-cel) for people with high-risk smoldering multiple myeloma. It aims to prevent progression to active myeloma.
SalamancaAges 18 years+ - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
San Francisco, CaliforniaAges 1.5 years–18 years - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06745687Recruiting
BCMA/CD3 antibody for high-risk smoldering myeloma
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
TianjinAges 18–78 - NCT06488482RecruitingPhase 3
Short immunotherapy after melanoma surgery
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
HelsinkiAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT07560813Recruiting
Nutrition and food support for pregnant people with diabetes
This study helps pregnant people with type 1 or type 2 diabetes who struggle to afford healthy food. You'll receive nutrition counseling and access to fresh food through a local program to help manage your blood sugar and have a healthier pregnancy.
Columbus, OhioAges 18 years+ - NCT05124808Recruiting
Tight blood sugar targets in pregnant women with gestational diabetes
This study compares a tighter blood sugar goal versus a standard goal in pregnant people with gestational diabetes who are also overweight or obese. It may help find whether stricter blood sugar control improves pregnancy outcomes.
Birmingham, AlabamaAges 18–45
Hear when a new Pregnancy, High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pregnancy, high risk?
- Yes. Clin2 currently lists 362 recruiting pregnancy, high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pregnancy, high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pregnancy, high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.